By admin 
Dr. Hunter Jonus, a prominent researcher at Emory University’s Department of Pediatrics, has been designated as a CureSearch Young Investigator, a title that carries with it the responsibility of spearheading transformative research into one of the most challenging pediatric cancers: high-risk neuroblastoma. This recognition highlights the critical nature of her work in cellular immunotherapy, specifically the development and application of gamma delta ($gammadelta$) T cells to combat extracranial solid tumors. As the primary investigator of this initiative, Dr. Jonus is bridging the gap between laboratory discovery and clinical application, focusing on children who have exhausted traditional treatment options. Her research is currently fueling a first-in-child clinical trial at Children’s Healthcare of Atlanta, representing a pivotal moment in the evolution of pediatric oncology.
Understanding the Landscape of High-Risk Neuroblastoma
Neuroblastoma is a complex and often devastating malignancy that originates in the developing nervous system, specifically within the sympathetic nervous system tissues. It is the most common extracranial solid tumor found in children, frequently manifesting in the adrenal glands, neck, chest, or spinal cord. While some cases of neuroblastoma are manageable with standard protocols, approximately 50% of patients are diagnosed with "high-risk" disease. This classification is reserved for cases characterized by aggressive tumor growth, genetic mutations such as MYCN amplification, and a high likelihood of metastasis.
The prognosis for high-risk neuroblastoma remains one of the most significant hurdles in pediatric medicine. Despite intensive multi-modal therapies—including high-dose chemotherapy, surgical resection, radiation, and stem cell transplants—the survival rate for these patients hovers at approximately 50%. The situation becomes exponentially more dire for children who experience a relapse. Once high-risk neuroblastoma returns following initial chemotherapy, the overall survival rate plummets to below 20%.
Furthermore, the survivors of high-risk neuroblastoma often face a lifetime of complications. The "cure" often comes at a high cost, as the intensive toxicity of current treatments can lead to permanent hearing loss, cardiovascular issues, growth impairment, and a significantly elevated risk of developing secondary malignancies later in life. It is within this high-stakes environment that Dr. Jonus is working to introduce a more targeted, less toxic alternative through immunotherapy.
The Science of Gamma Delta T Cell Immunotherapy
At the heart of Dr. Jonus’s research is the utilization of gamma delta ($gammadelta$) T cells. Most conventional T cell therapies, such as the widely known CAR-T cell treatments used for leukemia, utilize alpha-beta ($alphabeta$) T cells. While effective in blood cancers, $alphabeta$ T cells require precise matching between donor and recipient to prevent graft-versus-host disease (GvHD), and they often struggle to penetrate and survive within the "hostile" microenvironment of solid tumors.
Gamma delta T cells offer a unique biological advantage. They represent a small subset of T cells that combine features of both the innate and adaptive immune systems. Crucially, $gammadelta$ T cells do not rely on traditional Major Histocompatibility Complex (MHC) recognition. This means they can be harvested from healthy donors, expanded in a laboratory setting (ex vivo), and administered to patients without the high risk of GvHD associated with other T cell types.
Dr. Jonus’s approach involves extracting these potent cells from healthy donors and using specialized techniques to multiply them into the billions. Once infused into the patient, these cells act as "living drugs," specifically seeking out and destroying neuroblastoma cells. By utilizing healthy donor cells, the therapy avoids the "exhausted" state often found in the T cells of patients who have already undergone heavy rounds of chemotherapy.
Chronology of Research and Clinical Implementation
The journey of this research from a conceptual framework to a clinical reality has followed a rigorous timeline of validation and testing.
- Laboratory Foundation (2018–2021): Dr. Jonus and her team at Emory University focused on the optimization of $gammadelta$ T cell expansion. This phase involved identifying the specific cytokines and growth factors required to make these cells not only numerous but also highly aggressive toward neuroblastoma cell lines in vitro.
- Pre-clinical Validation: Following successful lab tests, the research moved into animal models to demonstrate that the expanded cells could successfully migrate to tumor sites and reduce tumor burden without causing systemic toxicity.
- The CureSearch Partnership (2023–2024): With the support of the CureSearch Young Investigator program, the research received the necessary funding and institutional backing to transition into the clinical phase. This program is designed to support high-potential researchers whose work has a clear path to clinical trials.
- First-in-Child Clinical Trial (Ongoing): The research has culminated in a landmark clinical trial at Children’s Healthcare of Atlanta. This trial combines the infusion of expanded $gammadelta$ T cells with traditional chemoimmunotherapy. The goal is to determine the safety and preliminary efficacy of this combination in children with relapsed or refractory neuroblastoma.
Engineering the Next Generation of Cellular Defense
While the current clinical trial represents a massive leap forward, Dr. Jonus is already looking toward the next iteration of the therapy. One of the primary challenges in treating solid tumors with immunotherapy is the "immunosuppressive microenvironment"—a protective shield that tumors create to turn off the immune response.
To overcome this, Dr. Jonus is pioneering the engineering of $gammadelta$ T cells with Chimeric Antigen Receptors (CARs). By adding a CAR to the $gammadelta$ T cell, researchers can "program" the cell to recognize specific proteins found on the surface of neuroblastoma cells, such as GD2. This increases the precision of the attack.
Additionally, Dr. Jonus is exploring "cytokine secretion" engineering. By modifying the cells to secrete their own growth factors, the $gammadelta$ T cells can survive longer within the tumor environment, maintaining their killing power for extended periods. Her future plans also include the integration of immune checkpoint blockade. This involves using drugs or genetic modifications that prevent the tumor from sending "stop" signals to the T cells, essentially keeping the immune response in an "always-on" state until the malignancy is eradicated.
Supporting Data and Technical Analysis
The move toward $gammadelta$ T cell therapy is supported by a growing body of data suggesting that solid tumors require a multi-faceted immune approach. In previous studies of high-risk neuroblastoma, traditional CAR-T therapy (using $alphabeta$ cells) showed initial promise but often resulted in tumor escape, where the cancer returns because the T cells did not persist long enough or the tumor stopped expressing the target protein.
Data from Dr. Jonus’s preliminary work suggests that $gammadelta$ T cells may be less susceptible to these escape mechanisms. Because $gammadelta$ T cells possess multiple natural receptors for stress signals common in many types of cancer (not just a single engineered receptor), they are harder for the tumor to "hide" from. Furthermore, the ability to use "off-the-shelf" cells from healthy donors means that treatment can begin almost immediately upon a patient’s relapse, rather than waiting weeks for a patient’s own cells to be processed.
Institutional and Community Impact
The selection of Dr. Jonus as a CureSearch Young Investigator has been met with significant enthusiasm from the pediatric oncology community. CureSearch for Children’s Cancer, a national non-profit, focuses exclusively on funding research that has a high probability of reaching the clinic quickly. Their support of Dr. Jonus reflects a strategic shift in the field toward "precision medicine"—treatments tailored to the specific biological drivers of a child’s cancer.
In a statement regarding her selection, Dr. Jonus expressed the gravity of the mission: "I am ecstatic to be selected as a CureSearch Young Investigator and for the opportunity to conduct this meaningful research with significant potential to impact patients’ lives. I am hopeful for the future of $gammadelta$ T cell immunotherapy and its possibility to overcome barriers in the field of adoptive cell therapy so that more patients will be able to receive this powerful treatment approach."
The collaboration between Emory University and Children’s Healthcare of Atlanta (CHOA) is also a critical component of this success. CHOA is home to one of the largest pediatric cancer programs in the United States, providing Dr. Jonus with access to a diverse patient population and world-class clinical infrastructure. This partnership ensures that laboratory breakthroughs are translated into bedside care with maximum efficiency.
Broader Implications for the Future of Oncology
The implications of Dr. Jonus’s work extend far beyond neuroblastoma. If $gammadelta$ T cells prove successful in treating this aggressive solid tumor, the platform could theoretically be adapted for other pediatric "cold" tumors, such as osteosarcoma or Ewing sarcoma, which have similarly resisted traditional immunotherapy.
The shift toward engineering cells that can survive the harsh conditions inside a solid tumor is the "holy grail" of modern oncology. By focusing on cell longevity and the inhibition of checkpoint signals, Dr. Jonus is contributing to a global effort to make immunotherapy as effective for solid tumors as it has been for liquid cancers like leukemia.
Moreover, the emphasis on reducing long-term toxicities represents a shift in how "success" is defined in pediatric oncology. It is no longer enough to simply achieve remission; the goal is to achieve a cure that allows a child to grow into an adult with a high quality of life, free from the secondary health crises caused by the treatment itself.
As the clinical trial at Children’s Healthcare of Atlanta progresses, the medical community will be watching closely. The data gathered from these first young patients will provide the foundation for larger, multi-center trials that could eventually establish $gammadelta$ T cell therapy as a new standard of care. For the families of children with high-risk neuroblastoma, Dr. Jonus’s work offers more than just a new scientific methodology; it offers a tangible reason for hope in the face of a historically grim prognosis. Through the intersection of genetic engineering, immunology, and compassionate clinical care, the landscape of pediatric cancer treatment is being fundamentally rewritten.
